3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
10
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Interventions
tucatinib
1
pertuzumab
1
atezolizumab
1
Trastuzumab
1
Fulvestrant
1
Alpelisib
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
HER2-positive Metastatic Breast Cancer
×
Ado-Trastuzumab Emtansine
×
90 days
×
Clear all
NCT06595563
2026-05-07
ZEPHIR-02
Jules Bordet Institute
Phase 2
Recruiting
87 enrolled